N-terminal acetylation and C-terminal amidation are often treated as routine options on a peptide order form. They still change molecular mass, charge, chromatographic behavior and the set of plausible impurities. When qualifying an N-terminal acetylated C-terminal amidated peptide supplier, place both termini in the material definition and require analytical evidence that distinguishes them from free-terminal variants.
Write terminal chemistry into the sequence
Use an explicit notation such as Ac–sequence–NH2 and define whether the residue numbering includes any added linker or tag. Do not rely on a product name ending in “amide,” which may be copied inconsistently between quotation, label and COA.
If only one terminus is modified, state the other as free acid or free amine. This prevents the supplier from applying its catalogue default. Terminal configuration must remain identical across reference, control and scale-up lots.
C-terminal amidation begins with the synthesis route
In solid-phase peptide synthesis, an amide-generating resin commonly determines the C-terminal functionality. Incorrect resin selection or cleavage can produce a free-acid analogue or other terminal impurity. For difficult sequences, deletion products containing the same terminal amide may complicate purification.
Ask the manufacturer to document resin identity and crude LC-MS. The final chromatogram alone does not reveal whether a terminal variant coelutes with the target.
N-terminal acetylation needs completion evidence
Acetylation is usually performed after chain assembly, but incomplete reaction leaves free-amine peptide. Over-acetylation of unintended sites can occur if side-chain protection or processing is poorly controlled. The supplier should define the reagent, endpoint and washing steps.
The expected mass shift supports completion, while LC-MS peak review should look specifically for the unacetylated mass. If the two forms are not chromatographically resolved, an extracted-ion comparison can be more informative than UV area purity alone.
Intact mass is necessary, not the whole identity package
The correct complete mass confirms that the dominant ion is consistent with both terminal modifications. It may not rule out an isobaric sequence error. For long, modified or high-value peptides, tandem MS or peptide mapping can strengthen sequence evidence.
Check whether the reported theoretical mass is monoisotopic or average and whether the calculation includes the correct termini. Counterion is usually assessed separately and should not be inferred from the peptide ion spectrum.
Terminal changes affect solubility and comparison studies
Acetylation removes a positive N-terminal charge, while amidation removes the negative charge of a C-terminal carboxylate. The net effect depends on sequence and pH. A modified peptide may dissolve differently from its free-terminal control and can shift retention on reversed-phase HPLC.
Run solubility checks at the intended concentration and matrix. Avoid forcing both variants into an unsuitable solvent merely for procedural symmetry. If the project compares modified and unmodified forms, report each material’s counterion, content and water.
Purity does not equal delivered peptide amount
HPLC area percentage measures the relative chromatographic signal under one method. It does not subtract water, acetate, TFA or residual solvent. Request net peptide content when researchers need molar equivalence between terminal variants.
For multiple vials, define whether the supplier fills by gross material weight or peptide-equivalent content. Bulk purity can remain constant while vial delivery varies.
- Explicit Ac–sequence–NH2 specification.
- Crude and final HPLC/LC-MS data.
- Search for unacetylated and free-acid variants.
- Correct theoretical-mass calculation and sequence evidence.
- Peptide content, counterion, water and vial-fill basis.
Do acetylation and amidation always improve stability? No. They can reduce some terminal reactions or better represent a native fragment, but they may also change solubility and assay behavior. The modification should follow the experimental design, not a generic preference.
Send the exact sequence, terminal forms, purity, content basis, scale and comparison controls with the RFQ. A qualified supplier should return a specification that makes every terminus auditable from batch record through vial label.